| Old Articles: <Older 6891-6900 Newer> |
|---|
 |
The Motley Fool
November 19, 2010
Brian Orelli |
Up 95%, but Still Risky as Heck That's an understatement for MELA Sciences.   |
The Motley Fool
November 19, 2010
Brian Orelli |
How to Get Rich Buying This Trend As the baby boomers get older, the number of medical procedures and drugs that the average American takes will increase. |
The Motley Fool
November 19, 2010
Brian Orelli |
One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
BusinessWeek
November 18, 2010
Jason Gale |
Bill Gates' Latest Challenge: Polio Bill Gates is brokering deals with drugmakers to make cheaper vaccines available. |
BusinessWeek
November 18, 2010
Drew Armstrong |
Guess Who Opposes Reversing the Individual Mandate in Health Reform? As Republicans take aim at the individual mandate in the health reform law, health-care industry groups are lobbying to preserve it. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? |
The Motley Fool
November 18, 2010
Brian Orelli |
Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge. |
The Motley Fool
November 18, 2010
Travis Hoium |
Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam. |
| <Older 6891-6900 Newer> Return to current articles. |
